Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis
Authors:
- 1 June 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Pediatrics
- Vol. 30 (3) , 372-377
Abstract
Purpose of review: The aim of this study was to describe the newest development in cystic fibrosis (CF) care, CF transmembrane conductance regulator (CFTR) modulator therapies. Recent findings: Phase II results showing CFTR modulator triple therapies are more effective than current CFTR modulators. Summary: CFTR modulator therapy targets the protein defective in CF and boosts its function, but the drug must match mutation pathobiology. Ivacaftor, a CFTR potentiator, was the first modulator approved in 2012, with impressive improvement in lung function and other measures of disease in patients with gating and other residual function mutations (∼10% of CF patients). In 2015, the combination of lumacaftor, a CFTR corrector, and ivacaftor was approved for patients homozygous for the F508del mutation (∼40–50% of the CF population) with positive but less impressive clinical response and 10–20% incidence of intolerance. A next-generation CFTR corrector, tezacaftor, with ivacaftor equally effective and better tolerated than lumacaftor, has also received US Food and Drug Administration approval. Novel CFTR correctors, entering Phase 3 trials in triple modulator combination with tezacaftor-ivacaftor, appear substantially more effective for patients who are homozygous for the F508del mutation and can provide benefit for patients with a single F508del mutation. This offers promise of effective CFTR modulator therapy for nearly 90% of CF patients.Keywords
This publication has 32 references indexed in Scilit:
- Novel personalized therapies for cystic fibrosis: treating the basic defect in all patientsJournal of Internal Medicine, 2015
- Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutationJournal of Cystic Fibrosis, 2014
- Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Mechanism-based corrector combination restores ΔF508-CFTR folding and functionNature Chemical Biology, 2013
- Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationChest, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationThorax, 2011
- Regulation of endogenous ENaC functional expression by CFTR and ΔF508-CFTR in airway epithelial cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- Cystic fibrosisThe Lancet, 2009
- Cystic FibrosisNew England Journal of Medicine, 2005